These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34436248)

  • 21. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.
    Fuzimoto AD
    J Integr Med; 2021 Sep; 19(5):375-388. PubMed ID: 34479848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
    Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
    Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells.
    Müller WEG; Neufurth M; Wang S; Tan R; Schröder HC; Wang X
    Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33327522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.
    Tripathi N; Tripathi N; Goshisht MK
    Mol Divers; 2022 Feb; 26(1):629-645. PubMed ID: 33400086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).
    Schepler H; Wang X; Neufurth M; Wang S; Schröder HC; Müller WEG
    Theranostics; 2021; 11(13):6193-6213. PubMed ID: 33995653
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic Applications of Fucoidans and their Potential to Act Against COVID-19.
    Yadav D; Song M
    Curr Pharm Des; 2022; 28(46):3671-3676. PubMed ID: 36475344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.
    Elseginy SA; Fayed B; Hamdy R; Mahrous N; Mostafa A; Almehdi AM; S M Soliman S
    Bioorg Med Chem Lett; 2021 Jul; 43():128099. PubMed ID: 33984473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
    Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicinal Purposes: Bioactive Metabolites from Marine-derived Organisms.
    Li T; Ding T; Li J
    Mini Rev Med Chem; 2019; 19(2):138-164. PubMed ID: 28969543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (M
    Naidu SAG; Tripathi YB; Shree P; Clemens RA; Naidu AS
    J Diet Suppl; 2023; 20(2):284-311. PubMed ID: 34821532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
    Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
    Front Immunol; 2022; 13():811430. PubMed ID: 35250984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homoseongomycin, a compound isolated from marine actinomycete bacteria K3-1, is a potent inhibitor of encephalitic alphaviruses.
    Lin SC; Lehman CW; Stewart AK; Panny L; Bracci N; Wright JLC; Paige M; Strangman WK; Kehn-Hall K
    Antiviral Res; 2021 Jul; 191():105087. PubMed ID: 33965437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.